Acorda Therapeutics, Inc. recently presented the results of its Phase 2b study of CVT-301, an inhaled levodopa (L-dopa) under development for patients with OFF episodes associated with Parkinson’s disease (PD). OFF episodes cause the re-emergence of PD motor symptoms, including muscle stiffness, impaired movement and tremor. Results from…
Amarantus BioScience Holdings, Inc, a company that develops diagnostics and treatments for syndromes in the fields of neurology, psychiatry, ophthalmology and regenerative medicine, recently announced the opening of the first clinical site in its Phase 2b trial that will assess the efficacy of eltoprazine in treating patients with Parkinson’s…
Cynapsus Therapeutics Inc. (CTH) has been granted an additional patent for its sublingual apomorphine portfolio by the U.S. Patent and Trademark Office (USPTO). Cynapsus focuses on developing a therapeutic option to address the off-episodes in patients with Parkinson’s disease called APL-130277, and the new patent is owned solely by the company. Cynpasus received…
In a recent study published in the journal Neuron, a team of researchers at the University of Bonn and at the German Center for Neurodegenerative Diseases (DZNE) led by Prof. Stefan Remy were able to identify in mice brains specific neural cells linked to movement and navigation…
The CEO of NeuroDerm Ltd. has been invited to discuss the company’s achievements at the Jefferies 2015 Healthcare Conference, taking place next month in New York. Oded S. Lieberman, PhD, will present a corporate overview of the company, as well as novel treatments being developed by NeuroDerm for the treatment of moderate to severe Parkinson’s disease. The…
Amarantus BioScience Holdings (AMBS), a company developing treatments and diagnostics for diseases in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, recently announced that it has completed research in which mesencephalic-astrocyte-derived neurotrophic factor (MANF) was administered to the substantial nigra and the putamen of pigs by convection-enhanced…
Italian pharmaceutical company Zambon S.p.A. and Newron Pharmaceuticals S.p.A. have announced plans to launch Xadago, a drug therapy for mid- to late-stage Parkinson’s disease, in Germany. The release of the treatment is the result of a partnership between the two companies, and Germany will become the first country to commercialize the drug. “The launch of…
Former Detroit Tigers player Kirk Gibson was diagnosed with Parkinson’s disease after being submitted to a series of tests. The diagnosis was announced through a statement from Fox Sports Detroit, where Gibson has been working as sports analyst since the beginning of the season. The former professional baseball player is 57 years…
Get regular updates to your inbox.